S&CO Inc. Has $2.76 Million Holdings in Stryker Co. (SYK)

S&CO Inc. lessened its holdings in shares of Stryker Co. (NYSE:SYK) by 6.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 15,545 shares of the medical technology company’s stock after selling 1,000 shares during the quarter. S&CO Inc.’s holdings in Stryker were worth $2,762,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Atlantic Trust LLC acquired a new position in Stryker during the 2nd quarter worth $105,000. Centaurus Financial Inc. acquired a new position in Stryker during the 2nd quarter worth $110,000. NuWave Investment Management LLC lifted its holdings in shares of Stryker by 3,245.0% in the third quarter. NuWave Investment Management LLC now owns 669 shares of the medical technology company’s stock valued at $119,000 after buying an additional 649 shares during the period. Kaizen Advisory LLC lifted its holdings in shares of Stryker by 142.6% in the second quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock valued at $127,000 after buying an additional 442 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Stryker in the second quarter valued at $135,000. Institutional investors own 74.71% of the company’s stock.

In other news, CFO Glenn S. Boehnlein sold 750 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $178.17, for a total transaction of $133,627.50. Following the completion of the sale, the chief financial officer now directly owns 2,785 shares of the company’s stock, valued at $496,203.45. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Katherine Ann Owen sold 37,866 shares of the company’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total value of $6,317,563.44. Following the sale, the vice president now directly owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,031 shares of company stock valued at $6,520,313. 7.40% of the stock is currently owned by company insiders.

SYK has been the subject of several research analyst reports. Zacks Investment Research lowered Stryker from a “buy” rating to a “sell” rating in a report on Wednesday, July 18th. BTIG Research initiated coverage on Stryker in a report on Thursday, August 16th. They issued a “buy” rating and a $187.00 price objective for the company. Barclays initiated coverage on Stryker in a report on Monday, October 15th. They issued an “overweight” rating and a $198.00 price objective for the company. Oppenheimer set a $170.00 price objective on Stryker and gave the company a “hold” rating in a report on Friday, October 26th. Finally, Cantor Fitzgerald upped their price objective on Stryker from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, July 25th. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $181.15.

Shares of NYSE SYK opened at $169.79 on Thursday. Stryker Co. has a 12 month low of $146.80 and a 12 month high of $179.84. The firm has a market cap of $62.39 billion, a PE ratio of 26.16, a P/E/G ratio of 2.29 and a beta of 0.64. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 25th. The medical technology company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.68 by $0.01. Stryker had a return on equity of 28.00% and a net margin of 9.31%. The business had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.26 billion. On average, research analysts anticipate that Stryker Co. will post 7.28 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 31st. Stockholders of record on Friday, September 28th were issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 1.11%. The ex-dividend date of this dividend was Thursday, September 27th. Stryker’s dividend payout ratio is 28.97%.

COPYRIGHT VIOLATION WARNING: “S&CO Inc. Has $2.76 Million Holdings in Stryker Co. (SYK)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://sportsperspectives.com/2018/11/08/sco-inc-has-2-76-million-holdings-in-stryker-co-syk.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: Why do companies issue stock splits?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply